Andrea Apolo, M.D. on Twitter: "Nice summary of ongoing phase 3 randomized #immunotherapy clinical trials in 1st line #bladdercancer #GU18 https://t.co/roifTmpolW" / Twitter
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
AstraZeneca's Imfinzi records double bladder cancer failure, endangering first nod and dual-IO case | Fierce Pharma
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial - Clinical Genitourinary Cancer
Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? - European Urology
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Is Danube Pharmaceuticals Inc. late reporting EU clinical trials?
Continued) Key clinical trials' efficacy data of ICIs in patients with... | Download Scientific Diagram
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
Klinar | News
Cancers | Free Full-Text | Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma | HTML
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV
Meeting Updates Refine Approaches Toward Urothelial Carcinoma
Overview of Microbicide Clinical Trials | Download Table
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma - ScienceDirect
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
AstraZeneca Bladder Cancer Treatment Fails to Hit the Mark in Phase III Trial | BioSpace
Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis | BMJ Evidence-Based Medicine
Biomarkers for immunotherapy in bladder cancer: a moving target | Journal for ImmunoTherapy of Cancer
DANUBE Trial - UROONCO Bladder Cancer
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Management of metastatic bladder cancer - Cancer Treatment Reviews
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
